title: Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer.
abstract: OBJECTIVE
  Induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT) for locally advanced head and neck cancer has been studied in many clinical trials. This study was conducted to determine the response rate of IC with paclitaxel, ifosfamide, and cisplatin followed by CCRT with cisplatin for this group of patients, and the effect of the entire treatment on survival and time to disease progression.
  
  
  METHODS
  Thirty patients with advanced and unresectable head and neck cancer were treated with 2 cycles of induction paclitaxel/ ifosfamide/ cisplatin. If the primary tumor had a complete or partial response, patients were treated with 2 more cycles of IC followed by radiotherapy 70 Gy plus 3 cycles of cisplatin. For those with less than partial response or disease progression were treated according to the discretion of the physicians.
  
  
  RESULTS
  Ninety percent of patients had stage IV disease and 40% of them had primary tumor at maxillary sinus and nasal cavity. One patient (3%) achieved complete response (CR) and 18 patients had partial responses (PR) to IC. CCRT enhanced the response rate, resulting in a total of 3 CR (10%) and 16 PR (53%) to treatment. The median time to progression was 11.5 months. The median overall survival was 27 months. The most severe hematologic toxicity occurred during IC was grade3-4 neutropenia (40%). Grade 3-4 mucositis occurred in 68% of patients during CCRT.
  
  
  CONCLUSIONS
  This novel combined-modality treatment program, is toxic but feasible, and can be administered for selected patients with advanced and unresectable head and neck cancer. © 2010 Biomedical Imaging and Intervention Journal. All rights reserved.
authors: Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University, Thailand.
authors: I
authors: I
authors: Chitapanarux
authors: E
authors: E
authors: Tharavichitkul
authors: V
authors: V
authors: Lorvidhaya
authors: P
authors: P
authors: Sittitrai
authors: T
authors: T
authors: Pattarasakulchai
references: J Clin Oncol. 2003 Jan 15;21(2):320-6
references: 12525525
references: Semin Oncol. 2004 Dec;31(6):778-85
references: 15599855
references: Cancer. 2002 Jul 15;95(2):322-30
references: 12124833
references: J Natl Cancer Inst. 1994 Feb 16;86(4):265-72
references: 8158680
references: J Clin Oncol. 2005 Dec 1;23(34):8636-45
references: 16275937
references: J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
references: 8656441
references: J Clin Oncol. 1998 Apr;16(4):1325-30
references: 9552033
references: Lancet. 2000 Mar 18;355(9208):949-55
references: 10768432
references: Br J Cancer. 2000 Dec;83(12):1594-8
references: 11189100
references: N Engl J Med. 1991 Jun 13;324(24):1685-90
references: 2034244